样式: 排序: IF: - GO 导出 标记为已读
-
Existing and Emerging Technologies for Therapeutic Monitoring of Lithium: A Scoping Review. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-03-07 Santiago Pedraza-Sanabria, Seetal Dodd, Luis Fernando Giraldo-Cadavid, Karen Whittingham, Rosa-Helena Bustos
Lithium is an effective psychoactive drug. It has a narrow therapeutic margin, with subtherapeutic levels or intoxication commonly occurring. Therapeutic drug monitoring (TDM) of lithium has several barriers. This scoping review aims to describe and analyze existing and emerging technologies for lithium TDM and to describe the lithium quantification parameters (precision, accuracy, detection limit)
-
Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-03-05 Şükrü Alperen Korkmaz, Esra Koca, Özge Yılmaz, Tayfun Özbek, Muhammed Alperen Güçlü, Sadice Kızgın
It is still not well known whether antipsychotic monotherapy versus polypharmacy differs in terms of efficacy in the emergency department (ED) utilization, presentation with agitation/aggression, and rehospitalization in schizophrenia spectrum disorders (SSD) patients. This study aimed to determine the effectiveness of antipsychotic monotherapy and polypharmacy for these outcomes in the real world
-
Concentrations of Fluoxetine Enantiomers Decline During Pregnancy and Increase After Birth. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-2-29 Katherine L Wisner, Michael J Avram, Alfred L George, Tatiana V Abramova, Amy Yang, Steve N Caritis, Maged M Costantine, Catherine S Stika
Few studies of the effect of the dynamic physiologic changes during pregnancy on plasma concentrations of fluoxetine (FLX) have been published.
-
Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-2-29 Mieko Nagano, Yutaka Susuta, Hideaki Masui, Yumi Watanabe, Koichiro Watanabe
This post hoc analysis investigated whether a patient's underlying psychiatric disease (schizophrenia/schizoaffective disorder [SCHZ] or bipolar disorder/depressive disorder [MOOD]) influenced the efficacy or safety of valbenazine for tardive dyskinesia (TD) in an Asian population.
-
Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-2-29 Roger S McIntyre, Suzy Bubolic, Zhen Zhang, Erin M MacKenzie, François Therrien, Maia Miguelez, Matthieu Boucher
Anxiety symptoms in major depressive disorder (MDD) are frequent, and they decrease response to antidepressant treatment (ADT), and affect patient functioning. This post hoc analysis examined the efficacy of adjunctive brexpiprazole on individual depressive symptoms and functioning in patients with MDD with anxious distress.
-
Neurocognitive Functions After 6-Month Buprenorphine (Naloxone)-Based Opioid Agonist Maintenance Treatment: A Controlled Prospective Study. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-2-29 Abhishek Ghosh, Alka Shaktan, Ritu Nehra, Abhishek Verma, Devender K Rana, Chirag K Ahuja, Manish Modi, Paramjit Singh, Debasish Basu
Medications for opioid use disorder (OUD) may influence neurocognitive functions. Inadequate power, confounders, and practice effects limit the validity of the existing research. We examined the change in cognitive functions in patients with OUD at 6-month buprenorphine (naloxone) posttreatment and compared the cognitive performance of the buprenorphine-treated group with control subjects.
-
Predicting Conversion to Insulin Sensitivity With Metformin: A Promising Tool for Clinicians in Addressing Insulin Resistance and Improving Outcomes in Patients With Treatment Resistant Bipolar Depression. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-2-29 Jessica M Gannon, Marcos Sanchez, Katherine Lines, Kathleen Cairns, Claire Reardon, K N Roy Chengappa, Cynthia V Calkin
Insulin resistance (IR) changes the trajectory of responsive bipolar disorder to a treatment-resistant course. A clinical trial conducted by our group demonstrated that IR reversal by metformin improved clinical and functional outcomes in treatment-resistant bipolar depression (TRBD). To aid clinicians identify which metformin-treated TRBD patients might reverse IR, and given strong external evidence
-
Effect of Coffee and Chocolate Ingestion on Clozapine Dose and on Plasma Clozapine and Norclozapine Concentrations in Clinical Practice. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-2-29 Robert James Flanagan, Stephen John Obee, Alice Hyun Min Kim, Susanna Every-Palmer
Some reports point to dietary caffeine intake as a cause of increased plasma clozapine concentrations in certain patients.
-
Clozapine Use in 22q11.2 Deletion Syndrome: A Systematic Review of the Literature. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-02-12 Mark Ainsley Colijn
22q11.2 deletion syndrome confers significant risk for the development of schizophrenia. While current recommendations regarding the management of psychotic symptoms in affected individuals are generally in keeping with treatment guidelines for general schizophrenia populations, evidence for the use of clozapine has come from case reports and retrospective observational data. As no reviews on the topic
-
Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-01-26 Maiko Watanabe, Fuminari Misawa, Hiroyoshi Takeuchi
Clozapine is considered the gold standard medication for treatment-resistant schizophrenia (TRS). However, given that clozapine treatment is associated with the burden of regular blood monitoring and the risk of life-threatening adverse effects, high-dose olanzapine can serve as an alternative treatment. We conducted a bidirectional mirror-image study to evaluate the effectiveness of high-dose olanzapine
-
Group-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-01-23 Ning Lyu, Susan Abughosh, Tyler J Varisco, Ying Lin, Paul J Rowan, Hua Chen
Antipsychotic-associated weight gain (AAWG) is a common adverse effect of second-generation antipsychotic (SGA) medications among children and adolescents. This study applied group-based trajectory modeling to identify latent trajectories of AAWG among children and adolescents and associated risk factors.
-
Current Status and Treatment of Rapid Cycling Bipolar Disorder. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-01-17 Alessandro Miola, Mark A Frye, Leonardo Tondo, Ross J Baldessarini
Rapid cycling (RC) at ≥4 recurrent episodes per year in bipolar disorder (BD) has been recognized since the 1970s. We now comment on our recent review of the topic and extensive RC analysis in a large clinical cohort, emphasizing therapeutics research.
-
Pharmacoepidemiology and Clinical Correlates of Lithium Treatment for Bipolar Disorder in Asia. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-01-17 Yao Kang Shuy, Sanjana Santharan, Qian Hui Chew, Shih-Ku Lin, Wen-Chen Ouyang, Chih-Ken Chen, Seon-Cheol Park, Ok-Jin Jang, Jun Hyuk Park, Kok-Yoon Chee, Kwong Sen Ding, Jamaline Chong, Ling Zhang, Keqing Li, Xiaomin Zhu, Chonnakarn Jatchavala, Pornjira Pariwatcharakul, Roy A Kallivayalil, Sandeep Grover, Ajit Avasthi, Moin Ansari, Margarita M Maramis, Paing Phyo Aung, Chay Hoon Tan, Yu-Tao Xiang,
As clinical practices with lithium salts for patients diagnosed with bipolar disorder (BD) are poorly documented in Asia, we studied the prevalence and clinical correlates of lithium use there to support international comparisons.
-
Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-01-17 Pragya Thaman, Caitlin E Kulig, Daniel Greer
Schizophrenia is a chronic, debilitating mental illness that incurs a large economic burden. Decreasing hospital readmissions is a priority in health care to improve patient quality of life and decrease health care costs. Determining ways to prevent readmissions such as improving access to long-acting injectable (LAI) antipsychotics is important to assess.
-
Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2024-01-16 Susan L McElroy, Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Francisco Romo-Nava
Obesity is common among persons with bipolar disorder (BD). Liraglutide 3.0 mg/d subcutaneous injection is indicated for chronic weight management and associated with minimal adverse neuropsychiatric effects. This study evaluated whether liraglutide 3 mg/d reduced body weight, improved metabolic factors and eating psychopathology, and was safe and well tolerated in persons with stable BD who were obese
-
Direct-to-Consumer Advertising Survey of Psychiatrists in Massachusetts and Michigan. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-12-15 Bennett E Wechsler, Richard Balon, Richard I Shader, Anthony J Rothschild
The goals of this preliminary study were to survey psychiatrists and to examine the impact of advertisements on their prescription of psychotropic medications. The study specifically looked at psychiatrists in Massachusetts and Michigan, as the authors were able to readily contact the members of their respective state psychiatric societies.
-
Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-12-15 Fatemeh Mohammad-Gholizad, Iman Karimzadeh, Ebrahim Moghimi-Sarani, Mahdi Arshadi, Negar Mortazavi
Clozapine, a second-generation antipsychotic medication, is mainly indicated for managing treatment-resistant schizophrenia. Among all the nonthreatening adverse effects of clozapine, sialorrhea is a stigmatizing complication occurring in approximately 31.0% to 97.4% of patients. In this study, 2 topical agents (atropine eye drop and ipratropium nasal spray) and a systemic medication (amitriptyline)
-
Effects of Clozapine on Cortical Inhibition: A Transcranial Magnetic Stimulation Follow-up Study. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-12-15 Melike Karaçam Doğan, Fatma Gökçem Yildiz, Çağri Mesut Temuçin, Aygün Ertuğrul
Preclinical and clinical investigations have revealed deficits in cortical inhibition in individuals with schizophrenia. Transcranial magnetic stimulation, a commonly used noninvasive measurement technique, is used for assessing these deficits. Limited research has been conducted on the effects of antipsychotic medications on cortical inhibition. This study aimed to evaluate the effects of clozapine
-
Clozapine- and Lithium-Associated Myoclonus: The Kindling Effect. A Case Report and Literature Review. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-30 Omar Elmarasi,Safaa Abdelhady,Aum Pathare,Yassir Mahgoub
-
Methylphenidate-Associated Ecchymosis in a Young Patient With Poststroke Attention Deficit. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-30 Muhamad Faizal Zainudin,Wan Nabilah Wan Jamil,Muhammad Mahdi Abdul Razak
-
Hypersensitivity to Psychotropic Medications in a Patient With 17q12 Microdeletion Syndrome: A Case Report. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-30 Shivali Patel,Mauran Sivananthan
-
Prevalence and Correlates of Serotonin Syndrome in Real-World Inpatients. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-30 Gabriele Di Salvo, Giorgia Porceddu, Camilla Perotti, Giuseppe Maina, Gianluca Rosso
Serotonin syndrome (SS) is a potentially life-threatening adverse drug reaction due to an increased central and peripheral serotonin activity, which usually presents as a triad of behavioral changes, neuromuscular excitability, and autonomic instability. Probably SS is often misdiagnosed, and its symptoms are mistaken for psychiatric symptoms or general medical issues: the true incidence of SS is not
-
Aripiprazole and Other Third-Generation Antipsychotics as a Risk Factor for Impulse Control Disorders: A Systematic Review and Meta-Analysis. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-27 Benjamin David Williams, Kenn Lee, Silas Okey Ewah, Kishen Neelam
Increasing evidence suggests an association between third-generation antipsychotics (TGAs) and impulse control disorders (ICDs). This is thought to be due to their partial agonism of dopamine receptors. However, neither the relative nor absolute risks of ICDs in those prescribed TGAs are well established. To inform clinical practice, this systematic review and meta-analysis summarizes and quantifies
-
Efficacy and Safety of Risperidone in Patients With Delirium: The RIDDLE Pilot Study. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-27 Patrick Viet-Quoc Nguyen, Thien Tuong Minh Vu
The cornerstone treatment of delirium is to assess and treat its underlying causes and prevent further complications. Drug therapy may be necessary to control agitation and behavioral symptoms associated with delirium. The aim of this pilot study was to evaluate the feasibility of a randomized placebo controlled trial to evaluate the efficacy and safety of risperidone in the treatment of delirium.
-
The Placenta and Psychiatry: Reinforcing Information. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-17 Richard I Shader
-
A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, Principles, and Practical Resources. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-12 Sara Palumbo, Veronica Mariotti, Silvia Pellegrini
Pharmacogenetics (PGx) studies the genetic factors underlying interindividual variability in drug response. Only a few countries around the world are already using PGx testing in psychiatric clinical practice, whereas others are still far from adopting it. The main barrier to the clinical adoption of PGx testing seems to be the limited knowledge among psychiatrists regarding the clinical relevance
-
Sleep Quality After Quetiapine Augmentation in Patients With Treatment-Resistant Depression and Personality Disorders. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-6 Christophe Moderie, Jacob D King, Nicolas Nuñez, Stefano Comai, Gabriella Gobbi
Quetiapine is a first-line augmenting agent for treatment-resistant depression (TRD) and is used off-label in insomnia. Quetiapine and its active metabolite norquetiapine act mostly on 5-HT2A, 5-HT2C, H1, and D2 as antagonists and on 5-HT1A as partial agonists. Patients with TRD often have comorbid personality disorder (PD), and evidence suggests an association between sleep disturbance and recovery
-
Effect of Cigarette Smoking on Clozapine Dose and on Plasma Clozapine and N-Desmethylclozapine (Norclozapine) Concentrations in Clinical Practice. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-11-6 Robert James Flanagan, Samora Hunter, Stephen John Obee
Cigarette smoking enhances plasma clozapine clearance and thus affects the clozapine dose requirement.
-
Adjunctive Docosahexaenoic Acid in Residual Symptoms of Depression and Anxiety. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-10-25 Michael Piperoglou,Malcolm Hopwood,Trevor R Norman
OBJECTIVE The aim of the study is to examine the efficacy of omega-3 fatty acid as an adjunct to ongoing pharmacological treatments in patients with residual symptoms of depression and anxiety. METHODS/PROCEDURES This randomized, double-blind, placebo-controlled, cross-over trial was conducted at a single private practice site. Participants were drawn from patients attending the practice.Patients meeting
-
Neuroleptic Malignant Syndrome Associated With Lurasidone: A Case Report. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-10-23 Samuel Pàmpols-Pérez,Arnau Gisbert-Solà,Belen Resa-Pérez,Andrea Jiménez-Mayoral,Irene Forcada-Pach,Vicent Llorca-Bofi
-
Surge of Midazolam Use in the Midst of Lorazepam Shortage. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-10-21 Tonia T Liu,Emma D Frost,Jack Donlon,Roshni M Gandhi,Tarannum Mohammadi,Briana P Murray,Mujeeb U Shad,Maju Mathew Koola
BACKGROUND Lorazepam is a widely prescribed benzodiazepine that is used to manage anxiety, insomnia, and status epilepticus and is used for pre-anesthetic care as well as several off-label indications including aggression, alcohol withdrawal, panic disorder, chemotherapy-associated anticipatory nausea, and catatonia. Recent increases in demand, manufacturing changes, and quality control issues have
-
Seizure, Rhabdomyolysis, and Hypoglycemia in a Patient With Venlafaxine Poisoning. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-10-18 Akif Yarkaç,Çağri Safa Buyurgan,Ataman Köse,Seyran Bozkurt Babuş
-
High-Dose Methylphenidate and Carboxylesterase 1 Genetic Variability in Patients With Attention-Deficit/Hyperactivity Disorder: A Case Series. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-10-18 Andrie C Westerkamp, Rob Rodrigues Pereira, Vera R Huitema, Ester A M Kouwert, Maja Matic, Ron H N van Schaik, Nieko Punt, Robert A Schoevers, Daan J Touw
Methylphenidate (MPH) is widely used to reduce symptoms of attention-deficit/hyperactivity disorder. Methylphenidate is metabolized by the carboxylesterase 1 (CES1) enzyme. Some patients need a very high dose of MPH to reach desired clinical effects, without having adverse effects. This may be due to differences in MPH pharmacokinetics (PK), potentially caused by DNA variants in CES1, the gene encoding
-
Tardive Dyskinesia Suppressed With Ginkgo Biloba. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-10-17 Petros D Petridis,Ari B Jaffe,Joshua T Kantrowitz,Jack Grinband
-
Pleural Effusion Associated With Divalproex Sodium: A Case Report and Literature Review. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-10-12 Pei Chen,Yang Yang,Yumeng Guo,Jing Li,Guishan Wang,Haining Yuan
-
Pramipexole as an Augmentation Strategy to Electroconvulsive Therapy in the Treatment of Bipolar Depression Complicated With Parkinsonism: A Case Report. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-10-11 Laura Bueno,Agustín Bermejo,Marta Gascón,Anna Giménez-Palomo,Néstor Arbelo,Helena Andreu,Oscar De Juan,Luis Olivier,Lourdes Navarro,Víctor Guerra,Inés Bartolomé,Sergi Salmerón,Iñaki Ochandiano,Pablo González-Martínez,Miquel Bioque,Lluc Colomer,Gerard Anmella,Cristian-Daniel Llach,Joaquín Gil-Badenes,Antoni Benabarre,Gabriel Pujol-Fontrodona,Eduard Vieta,Isabella Pacchiarotti
-
Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis?: A Case Report of Stimulant-Associated Psychosis. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-09-29 Hailey Kindt,Yassir Mahgoub
-
Clozapine-Associated Agranulocytosis: A Systematic Review. Is It Really So Frighteningly Common? J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-09-29 Carlo Magistri, Cristiano Mellini
Clozapine is a very effective therapeutic option for schizophrenic disorders that have been refractory to most other therapies. This extremely positive aspect clashes easily with an adverse effect of the drug that is deemed to be a very dangerous one: agranulocytosis. We asked whether the mandatory strict hematological follow-up prescribed in the black box warning of clozapine's label is proportioned
-
Paroxysmal Perceptual Alterations in Response to Flupentixol. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-09-26 Jonathan Phillips,Alvaro Barrera
-
The Need for Examining the Role of Psychostimulants in Treatment of Methamphetamine Use/Dependence. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-09-26 Richard Balon
-
Toxidrome of an Easily Obtainable Nootropic: A Case Report of Phenibut Intoxication and Withdrawal Delirium. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-09-12 Robin Martin, Ilana Buffenstein, Daniel Cho, Miki Kiyokawa
Phenibut (4-amino-3-phenyl-butyric acid) is a structural analog of GABA with central nervous system depressant and anxiolytic properties, developed in the former Soviet Union for anxiety, insomnia, and alcohol withdrawal. Its primary mechanism of action is believed to be a GABA-B receptor agonist-with high affinity at the α2δ subunit-containing voltage-dependent calcium channels and therefore gabapentinoid
-
Will ChatGPT3 Substitute for us as Clozapine Experts? J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-9-8 Jose de Leon, Carlos De Las Cuevas
ChatGPT3 is a new artificial intelligence program released on February 13, 2023.
-
Severe Alprazolam Withdrawal With Delirium and Psychosis. A Case Report and Literature Review. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-09-07 Oisín Conaty, Anne M Doherty, John Lally
In our report, and review of the literature, we present an important clinical lesson for the recognition and treatment of alprazolam withdrawal with complicated delirium and psychosis, and present a strong case for future treatment algorithms. Our case is unique due to the severity of behavioral disturbance associated with acute psychosis secondary to alprazolam withdrawal and the significant quantity
-
The Relationship of Early Sleep Improvement With Response to Pharmacotherapy in Unipolar Psychotic Depression. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-08-31 Cornelis F Vos, Tom K Birkenhäger, Willem A Nolen, Walter W van den Broek, Sophie E Ter Hark, Arnt F A Schellekens, Robbert-Jan Verkes, Joost G E Janzing
Since insomnia and depression are interrelated, improved sleep early in antidepressant pharmacotherapy may predict a positive treatment outcome. We investigated whether early insomnia improvement (EII) predicted treatment outcome in psychotic depression (PD) and examined if there was an interaction effect between EII and treatment type to assess if findings were treatment-specific.
-
Vortioxetine: A Safe Treatment for Depression in a Medically Complex Patient With QTc Prolongation. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-08-25 Sean Lynch,Chelsea Eisenach,Seema Quraishi
-
Prophylactic Management of Women With Bipolar Disorder During Pregnancy and the Perinatal Period: Clinical Scenario-Based Practical Recommendations From A Group of Perinatal Psychiatry Authors. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-08-25 Faruk Uguz, Verinder Sharma, Philip Boyce, Crystal T Clark, Megan Galbally, Alexia Koukopoulos, Wendy Marsh, Anja Stevens, Adele Viguera
Many women with bipolar disorder experience episodes of illness or relapses over the perinatal period, especially in the immediate postpartum period. Risks associated with treated/untreated psychopathologies and fetal exposure to bipolar medications make the management of bipolar disorder during these periods challenging for clinicians and patients. In light of the available effectiveness and reproductive
-
Antidepressant-Associated Treatment Emergent Mania: A Meta-Analysis to Guide Risk Modeling Pharmacogenomic Targets of Potential Clinical Value. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-08-16 Nicolas A Nuñez, Brandon J Coombes, Lindsay Melhuish Beaupre, Francisco Romo-Nava, Manuel Gardea-Resendez, Aysegul Ozerdem, Marin Veldic, Balwinder Singh, Jorge A Sanchez Ruiz, Alfredo Cuellar-Barboza, Jonathan G Leung, Miguel L Prieto, Susan L McElroy, Joanna M Biernacka, Mark A Frye
The purpose of this study was to review the association between the SLC6A4 5-HTTLPR polymorphism and antidepressant (AD)-associated treatment emergent mania (TEM) in bipolar disorder alongside starting a discussion on the merits of developing risk stratification models to guide when not to provide AD treatment for bipolar depression.
-
Assessing Adherence to Clozapine: Practical Considerations. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-08-09 Robert J Flanagan, Samora Hunter, Stephen J Obee
The clinical assessment of adherence to clozapine may prove difficult.
-
Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-08-07 Phillipa Louise Brothwood,Mina Husain,Jessica Pinson,Ebenezer Oloyede,Patrick Davey,Eromona Whiskey
-
Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-08-07 Lakshmi Jogi,Onia Subu,Pavithra Jaishankar,Vijay Kumar
-
A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-08-04 Nicholas Tkach,Douglas J Opler
-
The Yale University Open Data Access Project: A Resource for Research in Psychopharmacology. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-28 Matthew Roughley,Julie Bertrand,Suzanne Reeves
-
An Open-Label Study of Adjunctive Dextromethorphan/Quinidine in Treatment-Resistant Depression. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-27 Philip R Wang, Mani Yavi, Holim Lee, Yasmine Kotb, Lorie Shora, Lawrence T Park, Carlos A Zarate
Approximately one third of individuals with major depressive disorder have treatment-resistant depression (TRD). Glutamatergic modulators such as the N-methyl-d-aspartate receptor antagonist ketamine have rapid and robust antidepressant effects, but their use has been limited by accessibility and route of administration. This open-label pilot study assessed the adjunctive antidepressant efficacy of
-
Clinician Reasons for Stopping Clozapine: A Retrospective Cohort Study. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-27 Sandeep Grover, Nishtha Chaurasiya, Subho Chakrabarti
Little information is available on clozapine discontinuation rates in developing country settings.
-
Aripiprazole for the Treatment of Landolt's Forced Normalization. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-26 Jose Alvarez-Vazquez,Mónica Grande-Seijo,Luis Martinez Agulleiro,Jose Manuel Crespo Iglesias
-
Ketamine for Treatment-Resistant Depression and Suicidality in Adolescents: An Observational Study of 3 Cases. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-20 Rebecca Marshall,Karlo Valle,David Sheridan,Jay Kothari
-
Valacyclovir-Associated Catatonia: A Case Highlighting Its Neuropsychiatric Adverse Effects. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-14 HoLim Lee,Samantha Ongchuan Martin,Min Lee,Sahil Munjal
-
Erythema Multiforme in a Drug-Naive Patient of Obsessive-Compulsive Disorder Initiated on Fluoxetine. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-14 Arghya Pal,Rashmi Shukla,Mohammed Ahsan,K Geetha
-
Omicron Variant Infection May Not Exert an Influence on Serum Levels of Clozapine. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-14 Masaru Nakamura,Takahiko Nagamine
-
Efficacy of Brexpiprazole Combination Therapy on Anhedonia in a Case of Treatment Resistant Bipolar II Depression. J. Clinical Psychopharmacol. (IF 2.9) Pub Date : 2023-07-14 Mauro Scala,Laura Biondi,Chiara Fabbri,Alessandro Serretti